Gilead Sciences (NASDAQ:GILD) Upgraded to “Hold” at Daiwa America

Gilead Sciences (NASDAQ:GILD) was upgraded by equities research analysts at Daiwa America to a “hold” rating in a note issued to investors on Monday,Zacks.com reports.

GILD has been the subject of several other research reports. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 21st. Leerink Partners raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and lifted their target price for the company from $74.00 to $96.00 in a report on Monday, October 21st. Truist Financial raised their price objective on shares of Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research report on Friday, November 8th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, November 7th. Finally, Cantor Fitzgerald increased their target price on Gilead Sciences from $70.00 to $80.00 and gave the stock a “neutral” rating in a research note on Thursday, November 7th. Twelve equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have given a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.00.

Gilead Sciences Stock Up 1.0 %

Shares of NASDAQ:GILD opened at $88.63 on Monday. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The stock has a market cap of $110.46 billion, a P/E ratio of 984.78, a P/E/G ratio of 2.72 and a beta of 0.17. Gilead Sciences has a 1-year low of $62.07 and a 1-year high of $98.90. The firm has a fifty day moving average price of $87.15 and a 200 day moving average price of $76.52.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion for the quarter, compared to analyst estimates of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business’s revenue was up 7.0% on a year-over-year basis. During the same quarter last year, the company posted $2.29 earnings per share. Sell-side analysts predict that Gilead Sciences will post 4.38 EPS for the current year.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares in the company, valued at $6,545,480.06. The trade was a 27.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Merdad Parsey sold 25,590 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the transaction, the insider now owns 99,599 shares in the company, valued at approximately $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 56,947 shares of company stock worth $4,968,674. Corporate insiders own 0.16% of the company’s stock.

Hedge Funds Weigh In On Gilead Sciences

Several institutional investors and hedge funds have recently bought and sold shares of the stock. MQS Management LLC acquired a new position in Gilead Sciences in the first quarter valued at $250,000. Axxcess Wealth Management LLC lifted its stake in shares of Gilead Sciences by 24.5% in the 1st quarter. Axxcess Wealth Management LLC now owns 17,916 shares of the biopharmaceutical company’s stock valued at $1,312,000 after purchasing an additional 3,521 shares in the last quarter. Canada Pension Plan Investment Board grew its holdings in shares of Gilead Sciences by 6.1% during the 1st quarter. Canada Pension Plan Investment Board now owns 1,410,443 shares of the biopharmaceutical company’s stock worth $103,315,000 after purchasing an additional 80,666 shares during the period. Epoch Investment Partners Inc. increased its position in Gilead Sciences by 18.7% during the 1st quarter. Epoch Investment Partners Inc. now owns 887,978 shares of the biopharmaceutical company’s stock worth $65,044,000 after purchasing an additional 139,907 shares in the last quarter. Finally, Lazard Asset Management LLC raised its holdings in Gilead Sciences by 2.6% in the first quarter. Lazard Asset Management LLC now owns 969,733 shares of the biopharmaceutical company’s stock valued at $71,032,000 after buying an additional 24,683 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.